71% of patients found to experience a relapse compared with 43% who received the pills twice a week
Slow-release ketamine pills have been found to prevent relapse into depression, in a trial that could pave the way for a new treatment option for patients with severe illness.
Ketamine is already used as a treatment for depression when conventional antidepressant drugs and therapy have failed. But ketamine is currently only administered intravenously, which requires supervision in a clinic, and the National Institute for Health and Care Excellence ruled that a ketamine-like nasal spray should not be available on the NHS.
About Author
More Stories
Researchers create AI-based tool that restores age-damaged artworks in hours
European journalists targeted with Paragon Solutions spyware, say researchers
Australia has ‘no alternative’ but to embrace AI and seek to be a world leader in the field, industry and science minister says